Ultragenyx Pharmaceutical/$RARE
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
- Ticker
- $RARE
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,371
- Headquarters
- Novato, United States
- Website
- www.ultragenyx.com
RARE Metrics
BasicAdvanced
$1.6B
-
-$5.83
0.31
-
Price and volume
Market cap
$1.6B
Beta
0.31
52-week high
$39.89
52-week low
$12.73
Average daily volume
3.8M
Financial strength
Current ratio
1.726
Quick ratio
1.407
Long term debt to equity
-3.965
Total debt to equity
-4.232
Interest coverage (TTM)
-6.86%
Profitability
EBITDA (TTM)
-494.619
Gross margin (TTM)
-20.78%
Net profit margin (TTM)
-81.73%
Operating margin (TTM)
-69.46%
Effective tax rate (TTM)
-0.69%
Revenue per employee (TTM)
$520,000
Management effectiveness
Return on assets (TTM)
-24.22%
Return on equity (TTM)
932.27%
Valuation
Price to revenue (TTM)
2.332
Price to book
-5.62
Price to tangible book (TTM)
-3.59
Price to free cash flow (TTM)
-3.385
Free cash flow yield (TTM)
-29.54%
Free cash flow per share (TTM)
-4.913
Growth
Revenue change (TTM)
17.51%
Earnings per share change (TTM)
5.55%
3-year revenue growth (CAGR)
21.19%
10-year revenue growth (CAGR)
190.07%
3-year earnings per share growth (CAGR)
-17.13%
10-year earnings per share growth (CAGR)
1.02%
What the Analysts think about RARE
Analyst ratings (Buy, Hold, Sell) for Ultragenyx Pharmaceutical stock.
Analyst projections of the future price of Ultragenyx Pharmaceutical stock.
Bulls say / Bears say
Second-quarter revenue rose 28% year on year to a company record $214 million, while the net loss narrowed to $92 million. Ultragenyx reaffirmed 2026 revenue guidance of $730 million to $760 million and its target of profitability in 2027. (Ultragenyx)
The FDA approved FAYUVI as the first treatment for Sanfilippo syndrome type A, giving Ultragenyx a new product to launch in a severe, previously untreated disease. FDA reviewers found a meaningful advantage in cognitive scores versus natural history, although the evidence came from a small study. (Reuters, FDA)
GENGLYCOS offers another potential commercial growth driver: in a Phase 3 study, patients had a mean 61% reduction in daily cornstarch use at 96 weeks while maintaining glycaemic control. The therapy had received FDA accelerated approval for patients aged eight and older. (Ultragenyx)
The pivotal Phase 3 Aspire trial of apazunersen for Angelman syndrome missed both its primary and key secondary endpoints. Ultragenyx said it would review the programme, putting a major prospective pipeline asset in doubt. (SEC)
Setrusumab missed the primary fracture-reduction endpoint in both Phase 3 studies for osteogenesis imperfecta. Ultragenyx said UK regulators may require a new randomised study, while the FDA has yet to define what further evidence it would accept. (The Motley Fool)
The company remains loss-making and used $97 million of cash in operations in the second quarter, with $436 million in cash, equivalents and marketable securities at quarter-end. Its 2027 profitability goal therefore depends on continued sales growth, cost control and successful launches. (Ultragenyx)
Data summarised monthly by Lightyear AI. Last updated on 27 Oct 2026.
RARE Financial Performance
Revenues and expenses
RARE Earnings Performance
Company profitability
Upcoming events
No upcoming events
RARE News
AllArticlesVideos
What Ultragenyx Pharmaceutical (RARE) Said on Its Q3 Earnings Call
MarketBeat23 hours ago
Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 million
Proactive Investors4 weeks ago
Abeona Stands to Collect Royalties After Ultragenyx's FDA Approval — Here's the Rest of the Week
Benzinga2 months ago
Funds containing RARE
AllUSDEURGBP
Fund name | Fund size | $RARE weighting |
|---|---|---|
iShares Ageing Population$AGED | $953M | 0.13% |
iShares Ageing Population£AGES | $953M | 0.13% |
iShares Ageing Population€AGED | $903M | 0.13% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.10% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.10% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.